High ROIC Stocks
EXEL is currently part of our High ROIC Stocks screen, indicating it generates strong returns on invested capital.
EXELIXIS INC (EXEL) Stock Price & Overview
NASDAQ:EXEL • US30161Q1040
Current stock price
43.88 USD
-0.16 (-0.36%)
At close:
44.2666 USD
+0.39 (+0.88%)
After Hours:
The current stock price of EXEL is 43.88 USD. Today EXEL is down by -0.36%. In the past month the price increased by 6.3%. In the past year, price increased by 26.93%.
EXEL Key Statistics
52-Week Range32.38 - 49.62
Current EXEL stock price positioned within its 52-week range.
1-Month Range40.24 - 44.1852
Current EXEL stock price positioned within its 1-month range.
- Market Cap
- 11.396B
- P/E
- 15.84
- Fwd P/E
- 13.99
- EPS (TTM)
- 2.77
- Dividend Yield
- N/A
EXEL Stock Performance
Today
-0.36%
1 Week
+3.59%
1 Month
+6.30%
3 Months
+0.69%
Longer-term
6 Months +9.45%
1 Year +26.93%
2 Years +87.04%
3 Years +139.78%
5 Years +78.23%
10 Years +851.84%
EXEL Stock Chart
EXEL Stock Screens
EXEL currently appears in the following ChartMill screener lists.
High Free Cash Flow Stocks
EXEL is currently part of our High Free Cash Flow Stocks screen, indicating it generates strong cash flows relative to its price.
High Quality Stocks
EXEL is part of our High Quality Stocks screen, meaning it meets strict criteria for profitability, capital efficiency, and long-term growth consistency.
Undervalued Quality Stocks
EXEL appears in our Undervalued Quality Stocks screen, meaning it combines strong fundamentals with an attractive valuation.
EXEL Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to EXEL. When comparing the yearly performance of all stocks, EXEL turns out to be only a medium performer in the overall market: it outperformed 65.51% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
EXEL Fundamental Analysis
ChartMill assigns a fundamental rating of 8 / 10 to EXEL. EXEL scores excellent points on both the profitability and health parts. This is a solid base for a good stock.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
EXEL Earnings
On February 10, 2026 EXEL reported an EPS of 0.88 and a revenue of 598.66M. The company beat EPS expectations (7.04% surprise) and missed revenue expectations (-2.85% surprise).
Next Earnings DateMay 11, 2026
Last Earnings DateFeb 10, 2026
PeriodQ4 / 2025
EPS Reported$0.88
Revenue Reported598.663M
EPS Surprise 7.04%
Revenue Surprise -2.85%
EXEL Forecast & Estimates
27 analysts have analysed EXEL and the average price target is 47.77 USD. This implies a price increase of 8.87% is expected in the next year compared to the current price of 43.88.
For the next year, analysts expect an EPS growth of 13.25% and a revenue growth 11.13% for EXEL
Analysts
Analysts74.81
Price Target47.77 (8.87%)
EPS Next Y13.25%
Revenue Next Year11.13%
EXEL Groups
Sector & Classification
EXEL Financial Highlights
Over the last trailing twelve months EXEL reported a non-GAAP Earnings per Share(EPS) of 2.77. The EPS increased by 49.73% compared to the year before.
Income Statements
Revenue(TTM)2.32B
Net Income(TTM)782.57M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 33.73% | ||
| ROA | 27.51% | ||
| ROE | 36.21% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%83.33%
Sales Q2Q%5.63%
EPS 1Y (TTM)49.73%
Revenue 1Y (TTM)6.98%
EXEL Ownership
Ownership
Inst Owners102.75%
Shares259.71M
Float253.59M
Ins Owners2.23%
Short Float %10.39%
Short Ratio9.19
EXEL Latest News, Press Relases and Analysis
6 days ago - By: Chartmill
EXEL Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About EXEL
Company Profile
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. The company is headquartered in Alameda, California and currently employs 1,077 full-time employees. The company went IPO on 2000-04-11. The firm has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. The company is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The firm's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Company Info
IPO: 2000-04-11
EXELIXIS INC
1851 Harbor Bay Parkway
Alameda CALIFORNIA 94502 US
CEO: Michael M. Morrissey
Employees: 1077
Phone: 13026587581
EXELIXIS INC / EXEL FAQ
What does EXEL do?
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. The company is headquartered in Alameda, California and currently employs 1,077 full-time employees. The company went IPO on 2000-04-11. The firm has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. The company is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The firm's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
What is the stock price of EXELIXIS INC today?
The current stock price of EXEL is 43.88 USD. The price decreased by -0.36% in the last trading session.
Does EXELIXIS INC pay dividends?
EXEL does not pay a dividend.
What is the ChartMill rating of EXELIXIS INC stock?
EXEL has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 8 out of 10.
What is the market capitalization of EXEL stock?
EXELIXIS INC (EXEL) has a market capitalization of 11.40B USD. This makes EXEL a Large Cap stock.
What is the outstanding short interest for EXELIXIS INC?
The outstanding short interest for EXELIXIS INC (EXEL) is 10.39% of its float.